Review highlights advances in recombinant protein production in transgenic plants for pharmaceuticals and agriculture.
Studies on transgenic plants as the bioreactor to produce pharmaceutical and commericial valuable proteins has been advanced for over a decade. Some recombinant proteins produced in plants are now in clinical trials and have a promise future. Another expressed proteins in plants are agronomically valuable and can mediate resistance to pathogen infections, so could be an alternative method in molecular breeding of plants. In this review, we introduce some advances in this field.
No takes yet. Share an insight, caveat, or question.
HAO et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: